Overview
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Eligibility
Inclusion Criteria:
- * 177Lu-617 PSMA treatment scheduled for mCRPC
- Clinically stable as determined by the nuclear medicine clinicians
- Male
- ≥ 18 years of age
- Willing and able to provide informed consent
Exclusion Criteria:
- Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed